{
    "nct_id": "NCT03298451",
    "official_title": "A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma",
    "inclusion_criteria": "Inclusion criteria\n\n* HCC based on histopathological confirmation\n* No prior systemic therapy for HCC\n* Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C\n* Child-Pugh Score class A\n* ECOG performance status of 0 or 1 at enrollment\n\nExclusion criteria\n\n* Hepatic encephalopathy within past 12 months or requirement for medication to prevent or control encephalopathy\n* Clinically meaningful ascites\n* Main portal vein tumor thrombosis\n* Active or prior documented GI bleeding (eg, esophageal varices or ulcer bleeding) within 12 months\n* HBV and HVC co-infection, or HBV and Hep D co-infection\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}